Nevro
Nevro is a medical device company headquartered in Redwood City, California, and the creator of HFX, a comprehensive solution for individualized relief of chronic pain.
Last updated September 11, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Nevro is a medical device company headquartered in Redwood City, California, with the goal of helping more patients suffering from chronic pain achieve lasting relief. The company created HFX, described as one comprehensive solution for individualized relief of chronic pain, and developed 10 kHz Therapy, a next-generation spinal cord stimulation (SCS) approach. The Nevro Senza SCS System for 10 kHz Therapy received CE mark in 2010 and FDA approval in 2015, and is commercially available in Europe, Australia, and the United States. In the U.S., Nevro's SCS systems are approved to deliver all available SCS frequencies and the most waveform types in a single product. HFX is approved by the FDA with specific indications for painful diabetic neuropathy (PDN) and non-surgical back pain (NSBP).
History
Nevro is a medical device company headquartered in Redwood City, California, with the goal of helping more patients suffering from chronic pain achieve lasting relief. The company created HFX, described as one comprehensive solution for individualized relief of chronic pain. While traditional spinal cord stimulation (SCS) has been around for over 30 years, Nevro created a disruption by offering a next-generation approach called 10 kHz Therapy. The Nevro Senza SCS System for 10 kHz Therapy received CE mark in 2010 and FDA approval in 2015, and is commercially available in Europe, Australia, and the United States. In the U.S., Nevro's SCS systems are approved to deliver all available SCS frequencies and the most waveform types in a single product. HFX is approved by the FDA with specific indications for painful diabetic neuropathy (PDN) and non-surgical back pain (NSBP).
Products and positioning
One comprehensive solution for individualized relief of chronic pain, offering innovative technologies, advanced therapies, services and support, and meaningful evidence.
HFX
One comprehensive solution for individualized relief of chronic pain, offering innovative technologies, advanced therapies, services and support, and meaningful evidence.
10 kHz Therapy
A next-generation spinal cord stimulation (SCS) approach that provides patients with significant pain relief and no paresthesia.
Nevro Senza SCS System
The SCS system for 10 kHz Therapy; received CE mark in 2010 and FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
Controversies
2021
Jury finds Nevro infringed two Boston Scientific patents
A Delaware jury found that Nevro infringed two Boston Scientific patents and awarded Boston Scientific $20 million. Nevro said it disagreed with the finding and planned to appeal.
2020
Nevro files patent lawsuit against Nalu Medical
Nevro Corp. filed a patent-infringement lawsuit against Nalu Medical in the U.S. District Court for the District of Delaware, alleging that Nalu infringed Nevro patents covering the Senza system and HF10 therapy.
Recent events
Reported
Jury finds Nevro infringed two Boston Scientific patents[5]
A Delaware jury found that Nevro infringed two Boston Scientific patents and awarded Boston Scientific $20 million. Nevro said it disagreed with the finding and planned to appeal.
Reported
Nevro withdraws full-year guidance and provides third-quarter outlook[7]
Nevro withdrew its full-year 2021 guidance and provided third-quarter guidance, expecting worldwide revenue of approximately $90 million to $93 million.
Reported
Nevro updates 2021 revenue and adjusted EBITDA guidance[8]
Nevro updated its full-year 2021 worldwide revenue guidance to approximately $440 million to $450 million, from $430 million to $450 million, and its adjusted EBITDA guidance to $5 million to $15 million, from $0 million to $15 million.
Reported
Nevro introduces HFX brand identity[8]
Nevro highlighted the introduction of HFX, described as a comprehensive new brand identity combining its technologies, therapies and patient support.
Reported
Nevro launches Omnia upgrade powered by HFX Connect in the U.S.[9]
Nevro announced the full U.S. market launch of its Omnia upgrade, now powered by HFX Connect, which enables remote therapy optimization.
Reported
Nevro introduces the HFX brand identity[9]
Nevro announced the introduction of its HFX brand and an updated website, presenting HFX as a unified platform for its products, services, and patient support.
Reported
Nevro appoints Jon Shear as vice president of corporate development[10]
Nevro announced Jon Shear's appointment to the newly created position of Vice President, Corporate Development, effective immediately.
Reported
Nevro and Boston Scientific agree to dismiss California patent case[11]
Nevro and Boston Scientific agreed to dismiss the remaining claims in Nevro's California patent case concerning high-frequency spinal cord stimulation therapy. The dismissal remained subject to court approval; the parties said other patent cases would continue.
Reported
Nevro announces Roderick MacLeod as CFO[12]
Nevro announced Roderick ("Rod") MacLeod's appointment as Chief Financial Officer, effective June 15, 2020; he will succeed Andrew Galligan, who is retiring and will remain with the company during a transition period.
Reported
Nevro files patent lawsuit against Nalu Medical[6]
Nevro Corp. filed a patent-infringement lawsuit against Nalu Medical in the U.S. District Court for the District of Delaware, alleging that Nalu infringed Nevro patents covering the Senza system and HF10 therapy.
Sources16 sources
- 1Homepage - USAnevro.com
- 2About - USAnevro.com
- 3Providers - USAnevro.com
- 4Contact Us - USAnevro.com
- 5Jury finds Nevro infringed two Boston Scientific patentsprnewswire.com
- 6Nevro files patent lawsuit against Nalu Medicalprnewswire.com
- 7Nevro撤回全年指引并提供第三季度展望prnewswire.com
- 8Nevro更新2021年收入及调整后EBITDA指引prnewswire.com
- 9Nevro 在美国推出由 HFX Connect 提供支持的 Omnia 升级版prnewswire.com
- 10Nevro任命Jon Shear为企业发展副总裁prnewswire.com
- 11Nevro与波士顿科学同意撤销加州专利诉讼prnewswire.com
- 12Nevro宣布任命Roderick MacLeod为首席财务官prnewswire.com
- 13Nevro提供2020年补充财务指引prnewswire.com
- 14Nevro任命Karen N. Prange为董事会成员prnewswire.com
- 15Nevro Announces Second Quarter 2020 Financial Resultsprnewswire.com
- 16Nevro Reaches Agreement To Conclude Patent Lawsuit In California Against Boston Scientificfinanznachrichten.de
Cite this profile: Cite the canonical profile. /brand-wiki/nevro · Editorial policy · How profiles are compiled